Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics

Recent studies using mass spectrometry have discovered candidate biomarkers for amyotrophic lateral sclerosis (ALS). However, those studies utilized small numbers of ALS and control subjects. Additional studies using larger subject cohorts are required to verify these candidate biomarkers. Cerebrospinal fluid (CSF) samples from 100 patients with ALS, 100 disease control, and 41 healthy control subjects were examined by mass spectrometry. Sixty‐one mass spectral peaks exhibited altered levels between ALS and controls. Mass peaks for cystatin C and transthyretin were reduced in ALS, whereas mass peaks for posttranslational modified transthyretin and C‐reactive protein (CRP) were increased. CRP levels were 5.84 ± 1.01 ng/ml for controls and 11.24 ± 1.52 ng/ml for ALS subjects, as determined by enzyme‐linked immunoassay. This study verified prior mass spectrometry results for cystatin C and transthyretin in ALS. CRP levels were increased in the CSF of ALS patients, and cystatin C level correlated with survival in patients with limb‐onset disease. Our biomarker panel predicted ALS with an overall accuracy of 82%. Muscle Nerve 42: 104–111, 2010

[1]  S. Maleknia,et al.  Oxidation inhibits amyloid fibril formation of transthyretin , 2006, The FEBS journal.

[2]  Thomas Deufel,et al.  Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. , 2007, Clinical chemistry and laboratory medicine.

[3]  D. Chan,et al.  SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. , 2008, Clinical chemistry.

[4]  William R. Hogan,et al.  EPO-KB: a searchable knowledge base of biomarker to protein links , 2008, Bioinform..

[5]  T. Wieloch,et al.  Gene deletion of cystatin C aggravates brain damage following focal ischemia but mitigates the neuronal injury after global ischemia in the mouse , 2004, Neuroscience.

[6]  P. Scheltens,et al.  Inflammatory markers in AD and MCI patients with different biomarker profiles , 2009, Neurobiology of Aging.

[7]  K. Blennow,et al.  Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms , 2002, Dementia and Geriatric Cognitive Disorders.

[8]  K. Blennow,et al.  Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. , 2002, Dementia and Geriatric Cognitive Disorders.

[9]  R. Bowser,et al.  Protein biomarkers for amyotrophic lateral sclerosis , 2008, Expert review of proteomics.

[10]  K. Wakabayashi,et al.  Decreased Cystatin C Immunoreactivity in Spinal Motor Neurons and Astrocytes in Amyotrophic Lateral Sclerosis , 2009, Journal of neuropathology and experimental neurology.

[11]  P. Mcgeer,et al.  Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease , 2000, Brain Research.

[12]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[13]  T. Duong,et al.  C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease , 1997, Brain Research.

[14]  F. Zegher,et al.  Cerebrospinal fluid C-reactive protein in meningitis: diagnostic value and pathophysiology , 1986, European Journal of Pediatrics.

[15]  P. Mcgeer,et al.  Inflammatory processes in amyotrophic lateral sclerosis , 2002, Muscle & nerve.

[16]  Shu-hua Chen,et al.  Targeted protein quantitation and profiling using PVDF affinity probe and MALDI‐TOF MS , 2007, Proteomics.

[17]  N. Shimetani, K. Shimetani, M. Mori.  Levels of three inflammation markers, C-reactive protein, serum amyloid A protein and procalcitonin, in the serum and cerebrospinal fluid of patients with meningitis , 2001 .

[18]  Vanathi Gopalakrishnan,et al.  Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis , 2005, Journal of neurochemistry.

[19]  S. Kikuchi,et al.  Cystatin C in cerebrospinal fluid as a biomarker of ALS , 2009, Neuroscience Letters.

[20]  R. Nelson,et al.  Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. , 2006, Journal of proteome research.

[21]  Anders Wallin,et al.  Cystatin C in cerebrospinal fluid and multiple sclerosis , 2007, Annals of neurology.

[22]  D. Chan,et al.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. , 2008, Clinical chemistry.

[23]  H. Nakanishi.  Neuronal and microglial cathepsins in aging and age-related diseases , 2003, Ageing Research Reviews.

[24]  N. Shimetani,et al.  Levels of three inflammation markers, C-reactive protein, serum amyloid A protein and procalcitonin, in the serum and cerebrospinal fluid of patients with meningitis. , 2001, Scandinavian journal of clinical and laboratory investigation.

[25]  G. Bernardi,et al.  Differential post‐translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid , 2006, Proteomics.

[26]  W. Freeman,et al.  A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis , 2009, Neurology.

[27]  R. Bowser,et al.  Applying proteomics to the diagnosis and treatment of ALS and related diseases , 2009, Muscle and Nerve.

[28]  L. Ungar,et al.  Identification of potential CSF biomarkers in ALS , 2006, Neurology.

[29]  A. Sik,et al.  Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis , 2006, Nature Neuroscience.

[30]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[31]  O. Hardiman,et al.  Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004 , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[32]  V. Drory,et al.  Low‐grade systemic inflammation in patients with amyotrophic lateral sclerosis , 2009, Acta neurologica Scandinavica.

[33]  M. Staufenbiel,et al.  Cystatin C modulates cerebral β-amyloidosis , 2007, Nature Genetics.

[34]  A. Ludolph,et al.  Proteome Analysis of Cerebrospinal Fluid in Amyotrophic Lateral Sclerosis (ALS) , 2008, Neurochemical Research.

[35]  K. Blennow,et al.  Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease , 2008, Neurobiology of Aging.

[36]  H. Gendelman,et al.  Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment , 2003, Neurology.

[37]  Bruce G. Buchanan,et al.  DENDRAL and Meta-DENDRAL: Roots of Knowledge Systems and Expert System Applications , 1993, Artif. Intell..

[38]  J. Sass,et al.  The peak height ratio of S-sulfonated transthyretin and other oxidized isoforms as a marker for molybdenum cofactor deficiency, measured by electrospray ionization mass spectrometry. , 2002, Biochimica et biophysica acta.

[39]  S. Hirai,et al.  Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum , 1993, Neuroscience Letters.

[40]  P. Worms.  The epidemiology of motor neuron diseases: a review of recent studies , 2001, Journal of the Neurological Sciences.

[41]  K. Kamide,et al.  Amyloid formation in rat transthyretin: effect of oxidative stress. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[42]  F. Marincola,et al.  Inflammatory protein profile during systemic high dose interleukin‐2 administration , 2006, Proteomics.